Pneumococcal polysaccharide vaccine
Effectiveness, immunogenicity and safety of 23 valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
... It remains unclear why the rise in antibody levels after revaccination with pneumococcal polysaccharide vaccine is lower than after primary vaccination and if this might affect clinical effectiveness ...
12
Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis
... Interestingly, pneumococcal immunisation has been shown to elicit such anti-oxLDL anti- bodies in ...the pneumococcal polysaccharide vaccine (PPV), by inducing the production of anti-oxLDL ...
9
Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study
... Previous pulmonary infection was highly associated with poor clinical prognosis. This finding suggests that beneficial PPV23 effectiveness might be unachievable for older people with chronic pulmonary disease in the ...
8
Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
... 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal ...
7
The 23 valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double blinded, randomized, placebo controlled trial
... 23-valent pneumococcal polysaccharide vaccine (PPSV23) is effective in the prevention of invasive pneumococcal disease among high-risk older populations ...against pneumococcal ...
10
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
... 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine ...of pneumococcal disease in the elderly ...of vaccine-type ...
6
Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)
... A single dose of PCV13 may be admin- istered to children 6 through 18 years of age who are at increased risk of IPD because of sickle cell disease, ana- tomic or functional asplenia, HIV infec- tion or another ...
7
Safety of a 13 Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23 Valent Pneumococcal Polysaccharide Vaccine: An Open Label Trial
... 13-valent pneumococcal conjugate vaccine (PCV13) in 1049 individuals aged ≥68 years, who had previously been immunized with the unconjugated 23-valent pneumococcal polysaccharide ...
7
VH3 Antibody Response to Immunization with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Elderly Persons
... pneumococcal vaccine in pre- and postvaccination sera was determined by ELISA as described elsewhere (1). In brief, 96-well polystyrene plates (Costar; Corning Glass Works) were coated with 10 g/ml of ...
5
The effect of age on the response to the pneumococcal polysaccharide vaccine
... against vaccine sero- types 4, 6B, 9V, 14, 18C, 19F and 23F and vaccine- related serotype 6A were measured by 3rd generation ELISA using both C-PS and 22F serotype capsular PS absorption, as previously ...
8
Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis
... 23PS vaccine, and no data exist regarding the efficacy of these regimens for the prevention of pneumococcal ...23PS vaccine. Because 23PS vaccine provides a potentially expanded serotype ...
7
Use of Pneumococcal Vaccine in a Tertiary Care Centre in India
... invasive pneumococcal disease in African-American persons aged 35–49 years exceeds that for white persons aged ≥ 65 years and African Americans at all ages have at least twice the risk of invasive ...
120
Immunoreactivity of Five Monoclonal Antibodies against the 37-Kilodalton Common Cell Wall Protein (PsaA) ofStreptococcus pneumoniae
... pneumoniae pneumococcal sur- face adhesin A (PsaA) 37-kDa common cell wall ...licensed pneumococcal polysaccharide ...of pneumococcal antigen and may lead to the development of diagnostic ...
6
Effect of Combined Pneumococcal Conjugate and Polysaccharide Vaccination on Recurrent Otitis Media With Effusion
... 7-valent pneumococcal conjugate vaccine 3 to 4 weeks before and a 23-valent pneumococcal polysaccharide vaccine 3 months after tube ...7-valent pneumococcal conjugate ...
8
Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?
... 23-valent pneumococcal polysaccharide vaccine (PPV23) or the 13-valent pneumococcal conjugate vaccine (PCV13) and the effect on the pool of antigen-specific memory B cells (MBCs): a ...
8
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004
... current pneumococcal polysaccharide vaccine (23vPPV), which consists of 23 serotype antigens corre- sponding to over 90% of all invasive disease isolates, has been available since the early 1980's ...
12
Antibiotics Modulate Vaccine-Induced Humoral Immune Response
... a pneumococcal polysaccharide vaccine, a hepatitis B virus surface antigen (HBsAg) vaccine, and live attenuated Salmonella typhi (Ty21a) were investigated using a mouse ...the ...
6
An unusual presentation of a patient with severe hypogammaglobulinemia
... FIGURE 1 Antibody response to vaccinations. A, IgG anti‐tetanus antibodies before and after tetanus vaccination at the time of diagnosis. Gray bars represent antibody measurements in patient’s serum samples. The black ...
8
Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases – a longitudinal study
... of pneumococcal polysaccharide vaccine (PPV) in preventing invasive pneumococcal dis- ease (IPD), pneumonia and mortality for patients with chronic illnesses ...of vaccine response in ...
11
Effectiveness of the polysaccharide pneumococcal vaccine among HIV infected persons in Brazil: a case control study
... valent pneumococcal polysaccha- ride vaccine against invasive pneumococcal infection in the range of 30% to 80% among adults with normal immune function ...the polysaccharide vaccine ...
7